Objectives: The cationic biopolymer chitosan (CH) has emerged as a promising candidate adjuvant due to its safety profile and immunostimulatory properties. The presence of endotoxin contamination in biomaterials is generally underappreciated and can generate misleading results. It is important to establish a convenient methodology to obtain large amounts of high quality chitosan nanoparticles for biomedical applications.
Methods: We developed an easy method to generate endotoxin-free chitosan and assessed its purity using the Limulus amebocyte lysate assay and by measuring dendritic cell activation.
Key Findings: Purified chitosan-based formulations alone failed to induce production of the proinflammatory cytokines tumour necrosis factor alpha (TNF-α) and interleukin (IL)-6 in bone marrow-derived dendritic cells (BMDCs) generated from C57BL/6 mice, while maintaining its ability to promote IL-1β secretion in combination with the Toll-like receptor (TLR)-9 agonist, CpG. Moreover, BMDCs from C3H/HeN and TLR4-deficient mice, C3H/HeJ were stimulated with endotoxin-free chitosan-based formulations and no differences were observed in IL-6 and IL-1β secretion, excluding the involvement of TLR-4 in the immunomodulatory effects of chitosan.
Conclusions: The developed method provides simple guidelines for the production of endotoxin-free chitosan, ideal for biomedical applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jphp.13082 | DOI Listing |
Vaccine
May 2023
Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal; Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal. Electronic address:
The increasing awareness of endotoxin contamination has raised important questions during the study of the mechanism of action of the vaccine adjuvants. The endotoxins or lipopolysaccharides (LPS) can contaminate vaccine formulations contributing to result misinterpretations of the in vitro and in vivo studies. In this short communication, we considered the suitability of the Limulus amebocyte lysate (LAL) assay to quantify chitosan (Chit) nanoparticle (NP) endotoxin contamination to use them in a comparative in vitro immunotoxicology study using both LPS-free (LF) and non-LF Chit NPs.
View Article and Find Full Text PDFInt J Nanomedicine
October 2020
Orthopedic Research Laboratory, Hôpital Du Sacré-Cœur De Montréal, Université De Montréal, Montréal, Québec, Canada.
Purpose: Diethylaminoethyl-chitosan (DEAE-CH) is a derivative with excellent potential as a delivery vector for gene therapy applications. The aim of this study is to evaluate its toxicological profile for potential future clinical applications.
Methods: An endotoxin-free chitosan (CH) modified with DEAE, folic acid (FA) and polyethylene glycol (PEG) was used to complex small interfering RNA (siRNA) and form nanoparticles (DEAE-CH-PEG-FA/siRNA).
Front Bioeng Biotechnol
February 2020
Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Nanoparticles (NPs) assumed an important role in the area of drug delivery. Despite the number of studies including NPs are growing over the last years, their side effects on the immune system are often ignored or omitted. One of the most studied polymers in the nano based drug delivery system field is chitosan (Chit).
View Article and Find Full Text PDFJ Pharm Pharmacol
June 2019
Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Objectives: The cationic biopolymer chitosan (CH) has emerged as a promising candidate adjuvant due to its safety profile and immunostimulatory properties. The presence of endotoxin contamination in biomaterials is generally underappreciated and can generate misleading results. It is important to establish a convenient methodology to obtain large amounts of high quality chitosan nanoparticles for biomedical applications.
View Article and Find Full Text PDFEmerg Top Life Sci
October 2018
Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, Jiangnan University, Wuxi 214122, China.
Chitin oligosaccharides (CTOs) and its related compounds chitosan oligosaccharides (CSOs), collectively known as chitooligosaccharides (COs), exhibit numerous biological activities in applications in the nutraceutical, cosmetics, agriculture, and pharmaceutical industries. COs are currently produced by acid hydrolysis of chitin or chitosan, or enzymatic techniques with uncontrollable polymerization. Microbial fermentation by recombinant Escherichia coli, as an alternative method for the production of COs, shows new potential because it can produce a well-defined COs mixture and is an environmentally friendly process.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!